We have located links that may give you full text access.
Neurobehavioral symptom validity in U.S. Department of Veterans Affairs (VA) mild traumatic brain injury evaluations.
Journal of Clinical and Experimental Neuropsychology 2019 Februrary 5
INTRODUCTION: The use of the Neurobehavioral Symptom Inventory (NSI) by U.S. Department of Defense and Veterans Affairs (VA) providers for all mild traumatic brain injury (mTBI) evaluations led to the development of methods to screen for symptom exaggeration. The present study was designed to explore the clinical utility of three metrics-the Validity-10 scale, the NSI total score, and the mild Brain Injury Atypical Symptoms Scale (mBIAS)-relative to the results of several different criterion measures of symptom validity.
METHOD: Participants in this study were 82 U.S. military veterans referred for evaluations by a VA polytrauma clinic in the context of a history of mTBI. All participants were administered the Minnesota Multiphasic Personality Inventory-Second Edition-Restructured Form (MMPI-2-RF), NSI, and mBIAS.
RESULTS: None of the three scales displayed adequate accuracy at predicting failure on cognitive performance validity tests or on the MMPI-2-RF Fp-r scale. For the remaining MMPI-2-RF overreporting indices (F-r, Fs, FBS-r, RBS) and for an index based on elevation of any single MMPI-2-RF overreporting index, both the NSI total score and Validity-10 displayed high positive predictive power with adequate to good sensitivity values (39% to 76%).
CONCLUSION: These findings support the use of Validity-10 and NSI total score as symptom validity tests (SVTs) that can be used to assess for neurobehavioral symptom exaggeration.
METHOD: Participants in this study were 82 U.S. military veterans referred for evaluations by a VA polytrauma clinic in the context of a history of mTBI. All participants were administered the Minnesota Multiphasic Personality Inventory-Second Edition-Restructured Form (MMPI-2-RF), NSI, and mBIAS.
RESULTS: None of the three scales displayed adequate accuracy at predicting failure on cognitive performance validity tests or on the MMPI-2-RF Fp-r scale. For the remaining MMPI-2-RF overreporting indices (F-r, Fs, FBS-r, RBS) and for an index based on elevation of any single MMPI-2-RF overreporting index, both the NSI total score and Validity-10 displayed high positive predictive power with adequate to good sensitivity values (39% to 76%).
CONCLUSION: These findings support the use of Validity-10 and NSI total score as symptom validity tests (SVTs) that can be used to assess for neurobehavioral symptom exaggeration.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app